Selumetinib granted Orphan Drug Designation by FDA

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Selumetinib granted Orphan Drug Designation by FDA

SELUMETINIB granted Orphan Drug Designation by US FDA for treatment of UVEAL MELANOMA AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma. Uveal melanoma is a rare disease in which cancer cells form in the tissues of the eye. It is the most common primary intraocular malignancy in adults and comprises 5% of all melanomas1,2. "Uveal melanoma is a rare and devastating disease for which there are currently no effective treatment options once it spreads beyond the tissues of the eye. Selumetinib could potentially become the first effective treatment for these patients. The Orphan Drug Designation is an important regulatory advancement as we further our development plans for selumetinib in uveal melanoma," said Antoine Yver, Head of Oncology, Global Medicines Development at AstraZeneca. The Orphan Drug Designation programme provides orphan status to drugs and biologics, which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US3. Selumetinib, originally licensed from Array BioPharma Inc., inhibits the MEK pathway in cancer cells to prevent the tumour from growing. Data from a phase III study evaluating selumetinib in combination with chemotherapy in patients with first-line metastatic uveal melanoma is expected to be available later this year. In addition to uveal melanoma, selumetinib is being investigated in Phase III studies in KRAS mutation positive lung cancer and thyroid cancer and in Phase II in children with neurofibromatosis Type 1. Initial data from a combination study of selumetinib with other AstraZeneca pipeline molecules including AZD9291 (T790M-directed EGFR inhibitor) and MEDI4736 (anti-PD-L1) in non-small cell lung cancer will be presented at the American Society of Clinical Oncology (ASCO) annual meeting 2015. 1Egan KM, et al. Surv Ophthalmol 1988; 32: 239-51 2.Ramaiya KJ, Harbour JW. Expert Rev Ophthalmol 2007; 2: 939-46 3US Food and Drug Administration. Developing Products for Rare Diseases & Conditions http://www.fda.gov/ForIndustry/DevelopingProd...ions/defau l t.htm Accessed on 31 March 2015 About AstraZeneca in Oncology Oncology is a therapeutic area in which AstraZeneca has deep-rooted heritage. It will be potentially transformational for the company's future, becoming the sixth growth platform. Our vision is to help patients by redefining the cancer treatment paradigm and one-day eliminate cancer as cause of death. By 2020, we are aiming to bring six new cancer medicines to patients. Our broad pipeline of next-generation medicines is focused on four main disease areas - ovarian, lung, breast, and haematological cancers. These are being targeted through four key platforms - immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Esra Erkal-Paler                          +44 20 7604 8030 (UK/Global) Vanessa Rhodes                         +44 20 7604 8037 (UK/Global) Ayesha Bharmal                          +44 20 7604 8034 (UK/Global) Jacob Lund                                  +46 8 553 260 20 (Sweden) Michele Meixell                            + 1 302 885 6351 (US) Investor Enquiries Thomas Kudsk Larsen               +44 20 7604 8199     mob: +44 7818 524185 Karl Hård                                     +44 20 7604 8123 mob: +44 7789 654364 Eugenia Litz                                +44 20 7604 8233    mob: +44 7884 735627 Craig Marks                                +44 20 7 604 8591    mob: +44 7881 615764 Christer Gruvris                          +44 20 7604 8126     mob: +44 7827 836825 17 April 2015 -ENDS-

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 89

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
Smirnoff Launches Marvel Event with $12.99 Offer

Updated Category News Views 68

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move

Updated Category News Views 115

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Continue Reading
Amgen Q3 2026 Results: What Investors Should Know

Updated Category News Views 93

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

Continue Reading
Royce Global Trust: Insights on RGT's Performance

Updated Category News Views 80

Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Bloomberg Law Awards Series Celebrates Legal Excellence

Updated Category News Views 54

New Awards Shine Light on Corporate Legal Teams Here's one for the books: Bloomberg Law is rolling out a shiny new awards program called Inside In-House: Legal Departments of the Year. Now, this isn't some vanity affair because it's aimed at celebrating the folks in legal teams who make companies tick behind the scenes. Openings for nominations run through November 20,...

Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030

Updated Category News Views 132

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Continue Reading
BD's New Liverty™ TIPS Stent: A Game Changer?

Updated Category News Views 75

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

Continue Reading
Ascletis' ASC30 Achieves Significant HbA1c Reductions

Updated Category News Views 73

When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...

Continue Reading

Top 5 Most Recently Viewed Articles

Automotive Key Blank Market Insights for Smart Keys Growth

Updated Category News Views 97

The Expanding Landscape of the Automotive Key Blank Market The automotive key blank market is experiencing a transformative phase, poised to grow from USD 6.29 billion in 2025 to an impressive USD 9.67 billion by 2034. This remarkable growth reflects the industry’s ongoing adaptation to technological advancements, particularly the rising adoption of smart and automated...

Continue Reading
Innovations Drive Growth in the Meat Processing Equipment Sector

Updated Category News Views 231

Insights into the Expanding Meat Processing Equipment Market The global meat processing equipment market is anticipated to experience significant growth, projected to reach USD 16.36 billion by 2032. This remarkable increase from its value of USD 11.25 billion in 2024 represents a robust compounded annual growth rate (CAGR) of 4.86% from 2025 to 2032. The factors driving...

Continue Reading
Fed's Waller Advocates Rate Cuts in December Amid Labor Weakness

Updated Category News Views 173

Fed's Waller Emphasizes Importance of Rate Cuts Christopher Waller, a Governor at the Federal Reserve, has spoken out about the economic challenges facing the labor market. He is advocating for a reduction in the Fed’s policy rate during the next meeting, scheduled for December. His approach centers on the need to address the risks associated with a weakening labor...

Continue Reading
GIA-L Expands Innovation and Leadership with New Chapter Launch

Updated Category News Views 270

Global Initiative on Ageing and Longevity Launches U.S. Chapter The Global Initiative on Ageing and Longevity (GIA-L) has propelled its mission forward by launching a North American Chapter. This initiative is designed to accelerate innovation and foster significant business growth while addressing the changing demographics and needs of an aging population. The GIA-L...

Continue Reading
Deadline Alert: Faruqi & Faruqi's Investigation for Investors

Updated Category News Views 47

Investigating Extreme Networks: What You Need to Know Faruqi & Faruqi, LLP, a well-known national securities law firm, is currently looking into possible claims on behalf of investors in Extreme Networks, Inc. (NASDAQ: EXTR). The firm is reaching out to investors who have incurred losses exceeding $100,000 to discuss their options and legal rights. With the situation...

Continue Reading